medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 3

<< Back Next >>

Acta Med 2021; 19 (3)

COVID-19 vaccines

García OZR, Perón MLÁ, Ramírez VIO, Morales FJA, Mosqueda MEE, Vilchis HJ, Cruz SAX, Chávez AJE, Gutiérrez BD, Vásquez MLM, Valadez GY, Cortázar MLA, Vite VX, Ángel AAH, García LML, Bautista CP, Díaz RJB, Wong CRM

Language: Spanish
References: 58
Page: 429-444
PDF size: 473.01 Kb.


ABSTRACT

The appearance of the SARS-CoV-2 virus has generated a high degree of mortality and severe morbidity around the world, leading to the COVID-19 pandemic. This situation led to the emergence and development of different vaccines to prevent severe disease due to such malaise, as well as to reduce the number of deaths worldwide. The development of current COVID-19 vaccines is based on four platforms: genetic material of the virion, previously known viral vectors, inactivated SARS-CoV-2 virion, or including antigenic proteins of the virion, all of them capable of generating neutralising antibodies against the infection. These vaccines have gone through different phases of research, which have determined the effectiveness, safety, and immunogenicity of each one, as well as their use and approval by the World Health Organisation (WHO) and the different health regulatory agencies in each country. Among the vaccines currently accepted by the WHO for emergency use to control the pandemic are those manufactured by the companies Pfizer-BioNTech, Oxford-AstraZeneca, Johnson & Johnson, Moderna, Sinopharm and Sinovac.


REFERENCES

  1. Organización Mundial de la Salud. OMS: Declaración COVID-19: Cronología de la respuesta de la OMS a la COVID-19?. (Modificado 29 Ene 2021; Consultado 07 may 2021). Disponible en: https://www.who.int/es/news/item/29-06-2020-covidtimeline

  2. GAVI The Vaccine Alliance. COVAX: The COVID-19 vaccine race- weekly update. (Modified 03 Jun 2021; consulted 03 Jun 2021). Available in: https://www.gavi.org/vaccineswork/covid-19-vaccine-race#phases

  3. Organización Panamericana de la Salud. OPS: COVID-19 Fases de desarrollo de una vacuna. Mayo 2020. Available in: https://www.paho.org/es/documentos/covid-19-fases-desarrollo-vacuna

  4. Organización Mundial de la Salud. OMS: Vacunas e inmunización: ¿qué es la vacunación? (Modificado 30 Dic 2020; consultado 07 mayo 2021). Disponible en: https://www.who.int/es/news-room/q-a-detail/vaccines-and-immunization-what-is-vaccination?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQjws-OEBhCkARIsAPhOkIZ5WDg3D0mDZ403Dsf_82gwKuayCas-VEYE3lWN0MNWG-gdAciTI0YaAnr2EALw_wcB

  5. GAVI The Vaccine Alliance. There are four types of COVID-19 vaccines: here's how they work. Available in: https://ww.gavi.org/vaccineswork/there-are-four-types-covid-19-vaccines-heres-how-they-work

  6. Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021; 81: 495-501. doi: 10.1007/s40265-021-01480-7.

  7. Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nat Biomed Eng. 2020; 4: 1128-1133. doi: 10.1038/s41551-020-00658-w.

  8. Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048) Vaccines and Related Biological Products Advisory Committee. Briefing document. Meeting date: 10 December 2020.

  9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020; 383: 2603-2615. doi: 10.1056/NEJMoa2034577.

  10. Naik R, Smith M, Gottschalk L, Wollersheim S, Lee L, Huang L et al. Pfizer-BioNTech COVID-19 Vaccine EUA amendment review memorandum. Available in: https://www.fda.gov/media/148542/download

  11. Centros para el Control y la Prevención de Enfermedades. Visión general y seguridad de la vacuna contra el COVID-19 de Pfizer-BioNTech [Internet]. 21 de mayo de 2021 [Consultado 25/05/2021]. Disponible en: https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html

  12. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384 (15): 1412-1423. doi: 10.1056/NEJMoa2101765

  13. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021; doi: 10.1056/NEJMc2104974

  14. Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 202; 9 (2): 670-675. doi: 10.1016/j.jaip.2020.09.029.

  15. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016; 46: 907-922. doi: 10.1111/cea.12760

  16. European Medicines Agency. Covid-19 mRNA vaccine (Comirnaty): EU summary of product characteristics. [Accessed 24 Apr 2021] 2020. Available in: http:// ec.europa.eu

  17. CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States, December 14-23, 2020. MMWR Morb Mortal Weekly Rep. 2021; 70 (2): 46-51. doi: 10.15585/mmwr.mm7002e1.

  18. Jop de Vrieze. Pfizer's vaccine raises allergy concerns. Science. 2021; 371 (6524): 10-11. doi: 10.1126/science.371.6524.10

  19. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L et al. Preliminary Findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021. doi: 10.1056/NEJMoa2104983.

  20. Centers for Disease Control and Prevention. COVID-19 vaccines: interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. 2021. Available in: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html

  21. Oliver SE, Gargano JW, Marin M et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine-United States. 2020. MMWR Morb Mortal Wkly Rep. 2021; 69 (51-52): 1653-1656. doi: 10.15585/mmwr.mm695152e1.

  22. Zhang R. Vaccines and related biological products advisory committee meeting presentation. (17 December 2020). MRNA-1273. USA: Moderna.

  23. MRNA-1273 Sponsor Briefing Document Vaccines And Related Biological Products Advisory Committee Meeting Date, 17 December 2020, Available in: https://www.fda.gov/media/144452/download

  24. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK. Delayed large local reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med. 2021; 384 (13): 1273-1277. doi: 10.1056/NEJMc2102131.

  25. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396 (10249): 467-478. Available in: https://doi.org/10.1016/s0140-6736(20)31604-4

  26. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase ? trial. Lancet. 2021; 396 (10267): 1979-1993. Available in: https://doi.org/10.1016/s0140-6736(20)32466-1

  27. Ema.europa-eu. [Citado el 5 de mayo de 2021]. Disponible en: http://www.ema.europa-eu/en/documents/product-information-of-covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en-pdf

  28. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021; 384 (7): 643-649. Available in: https://doi.org/10.1056/nejmra2035343

  29. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397 (10269): 99-111. Available in: https://doi.org/10.1016/s0140-6736(20)32661-1

  30. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet. 2021; 397 (10277): 881-891. Available in: https://doi.org/10.1016/s0140-6736(21)00432-3

  31. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384:1885-1898. Available in: http://dx.doi.org/10.1056/NEJMoa2102214

  32. Medicines and Healthcare products Regulatory Agency. UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca [Internet]. GOV.UK. 2021 [Cited May 5, 2021]. Available in: https://www.gov.uk/government/news/uk-regulator-confirms-that-people-should-continue-to-receive-the-covid-19-vaccine-astrazeneca

  33. Europa.eu. [Cited May 5, 2021]. Available in: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021

  34. The first registered COVID-19 vaccine [Internet]. Sputnikvaccine.com. [Cited May 5, 2021]. Available in: https://sputnikvaccine.com/

  35. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396 (10255): 887-897.

  36. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2020; 396 (10255): 887-897. Published online Feb 2. Available in: http://dx.doi.org/10.1016/S0140-6736(21)00234-8

  37. Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396 (10249): 479-488. Available in: https://doi.org/10.1016/s0140-6736(20)31605-6

  38. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395 (10240): 1845-1854. Available in: https://doi.org/10.1016/s0140-6736(20)31208-3

  39. Organización Mundial de la Salud. La OMS añade la vacuna de Janssen a la lista de herramientas eficaces y seguras contra la COVID-19 [Internet]. Ginebra: Comunicado de prensa; 12 de marzo de 2021. [Consultado 5 mayo 2021]. Disponible en: https://www.who.int/es/news/item/12-03-2021-who-adds-janssen-vaccine-to-list-of-safe-and-effective-emergency-tools-against-covid-19#:~:text=La%20Organizaci%C3%B3n%20Mundial%20de%20la,el%20marco%20del%20Mecanismo%20COVAX

  40. Janssen Biotech Inc. VRBPAC Briefing Document. 26 Feb 2021, Available in: https://www.fda.gov/media/146219/download

  41. Janssen Biotech, Inc. Fact sheet for healthcare providers administering vaccine (vaccination providers). Last updated: April/23/2021. Available in: https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf

  42. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B et al. Safety and efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384: 2187-2201. Available in: https://www.nejm.org/doi/full/10.1056/NEJMoa2101544

  43. Johnson & Johnson. Johnson & Johnson Statement on COVID-19 Vaccine (Updated) [Internet]. New Brunswick NJ: Statement; April 13, 2021. [Accessed 5 Apr 2021]. Available in: https://www.jnj.com/johnson-johnson-statement-on-covid-19-vaccine-updated

  44. Johnson & Johnson. Johnson & Johnson Statement on April 23 CDC Advisory Committee Meeting on Company COVID-19 Vaccine [Internet]. NEW BRUNSWICK, N.J: Statement; April 23, 2021. [Accessed 5 Apr 2021]. Available in: https://www.jnj.com/johnson-johnson-statement-on-april-23-cdc-advisory-committee-meeting-on-company-covid-19-vaccine

  45. Bussel J, Connors J, Cines D. Thrombosis with Thrombocytopenia Syndrome - Hematology.org [Internet]. Hematology.org. Last updated 23 Apr 2021, [cited 06 May 2021]. Available in: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia

  46. Zhiwei Wu, Yaling Hu, Miao Xu, Zhen Chen, Wanqi Yang, Zhiwei Jiang et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet. 03/02/2021. Available in: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30987-7/fulltext

  47. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015

  48. Sinovac.com [Internet]. China; Sinovac; 5/02/2021. Available in: http://www.sinovac.com/product/showproduct.php?id=66

  49. Hitchings MDT, Ranzani OT, Scaramuzzini TMS, Barbosa OS, Almiron M, Said R. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: a test-negative case-control study. MedRxiv. 01/05/2021. Available in: nhttps://www.medrxiv.org/content/10.1101/2021.04.07.21255081v2

  50. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Ch K et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet. 2021; 21 (2): 181-192. Available in: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext#seccestitle160

  51. Centers for Disease Control and Prevention. Important information about HIV and COVID-19. 2021. Available in: https://espanol.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/hiv.html#print

  52. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Fu GG et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet. 2021. Available in: https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(20)30831-8.pdf

  53. medscape.com [Internet]. Emiratos Árabes Unidos: Medscape; December 09, 2020. Available in: https://www.medscape.com/viewarticle/942310

  54. Dirección de enfermedades inmunoprevenibles. Manual del Vacunador: Vacuna Sinopharm [Internet]. Argentina: Ministerio de Salud de Argentina; 2021 [Consultado 16/05/2021] Disponible en: https://bancos.salud.gob.ar/sites/default/files/2021-03/manual-vacunador-sinopharm_12-3-2021.pdf

  55. Bharatbiotech.com [internet]. India; Bharat Biotech; 2021 [Última actualización 2021]. Disponible en: https://www.bharatbiotech.com/covaxin.html

  56. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020; 383 (24): 2320-2332. doi: 10.1056/NEJMoa2026920

  57. Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021; 29 (4): 529-539.e3.

  58. Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge [Internet]. bioRxiv. 2020. Available in: http://dx.doi.org/10.1101/2020.08.18.256578




2020     |     www.medigraphic.com